<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1986">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135312</url>
  </required_header>
  <id_info>
    <org_study_id>OPTI-004</org_study_id>
    <nct_id>NCT05135312</nct_id>
  </id_info>
  <brief_title>Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging</brief_title>
  <official_title>Monitoring Nail Changes in Patients With Psoriatic Disease Treated With Etanercept Using Non- Invasive Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OptiSkin Medical</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OptiSkin Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis&#xD;
      treated with Enbrel® (etanercept) with optical coherence tomography (OCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to&#xD;
      infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new&#xD;
      study to monitor nail changes in patients with nail psoriasis treated with Enbrel®&#xD;
      (etanercept) with optical coherence tomography (OCT).&#xD;
&#xD;
      OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to&#xD;
      therapy, and identify changes even before they become apparent, potentially leading to&#xD;
      earlier treatment or prevention of future psoriatic arthritis.&#xD;
&#xD;
      Study-related care and medication are provided at no cost, and reimbursement for reasonable&#xD;
      local transportation may be available to qualified individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2021</start_date>
  <completion_date type="Anticipated">August 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NAPSI</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The NAPSI score is an established measure of nail disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OCT (clinical)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Optical Coherence Tomography is noninvasive imaging that can be used to monitor nail disease severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCT (sub-clinical)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Optical Coherence Tomography is noninvasive imaging that will be used to detect subclinical changes in otherwise healthy-appearing nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermoscopy</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Dermoscopy allows for the examination of the skin using skin surface microscopy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Psoriatic Nail</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>TNF-alpha inhibitors improve nail psoriasis.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Optical Coherence Tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe psoriasis&#xD;
&#xD;
          -  Psoriasis affecting the fingernails&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with Enbrel® (etanercept)&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Any personal or family history of any neurologic demyelinating disease&#xD;
&#xD;
          -  Receipt of investigational drugs or &quot;biologics&quot; within 4 weeks of the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orit Markowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OptiSkin Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Bressler, DO</last_name>
    <phone>2128283120</phone>
    <email>moshe@optiskinmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Halima Amro, BS</last_name>
    <phone>2128283120</phone>
    <email>halima@optiskinmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OptiSkin Medical</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Bressler, DO</last_name>
      <phone>212-828-3120</phone>
      <email>moshe@optiskinmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Halima Amro, BS</last_name>
      <phone>2128283120</phone>
      <email>halima@optiskinmedical.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OptiSkin Medical</investigator_affiliation>
    <investigator_full_name>Orit Markowitz MD</investigator_full_name>
    <investigator_title>Chief Medical Ofiicer</investigator_title>
  </responsible_party>
  <keyword>Psoriasis Nails</keyword>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>Enbrel</keyword>
  <keyword>Biologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

